Regeneron Rockets 6.7% on $1.25B Trading Surge Secures 92nd Volume Rank

On October 1, 2025, Regeneron Pharmaceuticals (REGN) saw a 6.70% surge in share price, with a trading volume of $1.25 billion—a 33.38% increase from the previous day. The stock ranked 92nd in volume among equities traded that session.

Recent developments suggest heightened market activity around the biotech giant. Analysts attributed the rally to renewed investor confidence in its pipeline advancements, particularly in late-stage trials for its flagship therapies. The elevated volume indicated strong institutional participation, though no material regulatory updates or partnership announcements were reported in the immediate term.

To set up an accurate back-test, key parameters require clarification: the screening universe (e.g., all U.S. stocks or a defined index), the timing of trade execution (open vs. close), transaction cost assumptions (e.g., 5 bps), and data granularity (daily bars with adjusted close). These details will determine the strategy's performance metrics when tested from January 3, 2022, to the current date.